BLOOD PRESSURE-LOWERING, ANTIHYPERTENSIVE TREATMENT AND INCIDENT DIABETES. (April 2021)

• Record Type: Journal Article
• Authors: Nazarzadeh, Milad; Bidel, Zeinab; Canoy, Dexter; Copland, Emma; Wamil, Malgorzata; Byrne, Karl Smith; Sundström, Johan; Teo, Koon; Davis, Barry R.; Chalmers, John; Pepine, Carl J.; Dehghan, Abbas; Bennet, Derrick A.; Smith, George Davey; Rahimi, Kazem
• Is Part Of: Journal of hypertension. Volume 39(2021)e-Supplement 1
• Publication Date: 2021-04
• Subjects: Hypertension -- Periodicals; Hypertension -- Periodicals; 616.132005
• DOI: 10.1097/01.hjh.0000744444.02673.7e
• Languages: English
• ISSNs: 1473-5598

Abstract

Abstract : Objective: To investigate the effect of blood pressure lowering and specific antihypertensives on the risk of new-onset type 2 diabetes, leveraging the strengths of both genetic data and individual-level data from randomised trials of blood pressure-lowering treatments. Design and method: We pooled individual-level data of 145, 939 participants from nineteen randomised clinical trials. We used stratified Cox proportional hazard models, with fixed treatment effects, and participants as the unit of analysis. Analyses were complemented with Mendelian randomisation studies using naturally randomised genetic variants associated with systolic blood pressure and genetic variants encoding the therapeutic targets of each drug class. Results: After a median of 4.4 years follow-up, 9, 883 participants were diagnosed with new-onset diabetes in clinical trials. Blood pressure-lowering treatment was found to reduce the risk of diabetes by 11% (hazard ratio [HR] per 5-mm Hg reduction in systolic blood pressure 0.89 [95% confidence interval [CI] 0.84 to 0.95]). Similarly, in the Mendelian randomisation study, each 5-mm Hg genetically-influenced lower systolic blood pressure was associated with an 11% lower risk of diabetes (odds ratio [OR] 0.88 [95% CI 0.84 to 0.92]). Evidence from genetic data and trials were also consistent in that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) reduced the risk of diabetes, and beta-blockers increased this risk. There was no evidence of an effect for calcium channel blockers and findings for thiazide diuretics were inconsistent; while genetic analysis showed a reduction in risk, the mostly indirect estimation from network analysis of trials suggested an increased risk compared with placebo. Conclusions: We found consistent evidence supporting that lowering blood pressure reduces the risk of new-onset diabetes. However, this protective effect was not uniform among different antihypertensive classes. Whereas ACEIs and ARBs reduced the risk of new-onset diabetes, the converse was observed with beta-blockers and possibly with thiazide diuretics. In determining which class of drug to use to manage elevated blood pressure, consideration of diabetes risk may help inform clinical decision-making.